Drugs that contain Cytarabine; Daunorubicin
1. Vyxeos patents expiration
VYXEOS's oppositions filed in EPO
VYXEOS Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431806 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr, 2025
(1 year, 2 days from now) | |
| US8518437 | CELATOR PHARMS | Lipid carrier compositions with enhanced blood stability |
Jun, 2026
(2 years from now) | |
| US7850990 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
| US9271931 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
| US8022279 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Sep, 2027
(3 years from now) | |
| US8092828 | CELATOR PHARMS | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Apr, 2029
(4 years from now) | |
| US10028912 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| US10835492 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| US10166184 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| New Product(NP) | Aug 03, 2020 |
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of re...
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
VYXEOS family patents
